Product Theaters
Sotytu (Deucaravacitinib): Oral Therapy Redefined
Friday, November 15 6:30 PM -8:00 PM
Buck Mountain Room
Speaker: Saurabh Singh, MD
Supported by Bristol Myers Squibb
Transformative Treatment Results in Plaque Psoriasis and Psoriatic Arthritis
Saturday, November 16 7:00 AM - 8:00 AM
Buck Mountain Room
Speaker: Ted Lain, MD
Supported by UCB
First in Class: TREMFYA is the first selective IL-23 inhibitor approved for adults with moderate to severe plaque psoriasis or adults with active psoriatic arthritis
Saturday, November 16 12:00 PM - 1:00 PM
Buck Mountain Room
Speaker: Nicole Seminara, MD
Supported by Janssen